Agenus Inc. (NASDAQ: AGEN) announced that four abstracts featuring its drug botensilimab have been accepted for presentation at the 2026 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE